Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Last trade$0.6279
Day change-$0.0109 (-1.71%)
Day range$0.617 – $0.658
Volume375,618
Market cap$61M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$60.86M
Price / earnings
—
Price / book
2.08×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.8×
Profitability
Earnings per share
-$0.17
Return on assets
-45.94%
Return on equity
-54.62%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.68×
Quick ratio
6.68×
Cash ratio
6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.31M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CGTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.25M
$2.64M
$2.7M
$2.52M
$2.6M
$2.5M
$2.99M
$2.57M
Research and development
$5.12M
$5.1M
$6.12M
$11.15M
$3.77M
$11.48M
$10.79M
$8.15M
Total operating expenses
$7.38M
$7.74M
$8.82M
$13.67M
$6.38M
$13.98M
$13.78M
$10.72M
Operating income
-$7.38M
-$7.74M
-$8.82M
-$13.67M
-$6.38M
-$13.98M
-$13.78M
-$10.72M
Interest expense
-$1K
-$3K
$0
$0
$0
-$3K
$0
$0
Income before taxes
-$4.15M
-$3.93M
-$4.57M
-$3.34M
-$4.93M
-$6.73M
-$8.48M
-$7.84M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.15M
-$3.93M
-$4.57M
-$3.34M
-$4.93M
-$6.73M
-$8.48M
-$7.84M
Net income attributable to common shareholders
-$4.15M
-$3.93M
-$4.57M
-$3.34M
-$4.93M
-$6.73M
-$8.48M
-$7.84M
EBITDA
-$7.37M
-$7.73M
-$8.81M
-$13.66M
-$6.36M
-$13.96M
-$13.78M
-$10.7M
Basic earnings per share
-$0.04
-$0.04
-$0.05
-$0.04
-$0.06
-$0.11
-$0.14
-$0.18
Diluted earnings per share
-$0.04
-$0.04
-$0.05
-$0.04
-$0.06
-$0.11
-$0.14
-$0.18
Recent news
Company coverage with links to the original publishers.
Cognition Therapeutics announced findings from its Phase 2 START study showing that plasma p-tau217 blood testing can improve clinical trial screening efficiency by reducing the need for costly PET imaging. The approach may decrease burden on participants and trial sites while maintaining biomarker eligibility assessment. Enrollment in the START study was completed in Q4 2025, with top-line results expected after participants complete 18 months of treatment.
Cognition Therapeutics, Inc. (CGTX) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 29.5% over the past three months, positioning it in the top 20% of Zacks-covered stocks and suggesting potential near-term stock price appreciation.
Cognition Therapeutics reported Q3 2026 financial results with a net loss of $4.1 million. The company achieved FDA alignment on primary endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies and received a patent for a novel crystalline form expiring in 2045. With $31.5 million in cash and $18.2 million in grant funds, the company estimates sufficient funding into Q4 2027. Top-line results from the Phase 2 START Study in Alzheimer's disease are anticipated in H2 2027.
Mesoblast Limited has appointed James M. O'Brien as its US-based Chief Financial Officer to support the company's transition to a fully integrated commercial organization, leveraging his extensive financial management experience in life sciences and biotechnology.
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.